Lv71
5000 积分 2022-05-11 加入
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
6小时前
已完结
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)
1个月前
已完结
Pancreatic cancer
3个月前
已完结
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
3个月前
已完结
Sentinel lymph node biopsy without systematic pelvic lymphadenectomy in females with early-stage cervical cancer: final outcome of the SENTIX prospective, single-arm, noninferiority, international trial
3个月前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
3个月前
已完结
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
3个月前
已完结
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial
3个月前
已完结
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)
3个月前
已完结
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer
4个月前
已完结
皖公网安备34019202002308
